Dimethylarginine dimethylaminohydrolase regulation

Carol Wadham, Arduino Aleksander Mangoni

Research output: Contribution to journalArticlepeer-review

48 Citations (Scopus)


Asymmetric dimethylarginine (ADMA), an endogenous methylated form of the amino acid L-arginine, inhibits the activity of the enzyme endothelial nitric oxide synthase, with consequent reduced synthesis of nitric oxide. ADMA is metabolised to L-citrulline and dimethylamine by the enzyme dimethylarginine dimethylaminohydrolase (DDAH). The modulation of DDAH activity and expression plays a pivotal role in regulating intracellular ADMA concentrations, with important effects on vascular homeostasis. For example, impairment in DDAH activity, resulting in elevated ADMA concentrations and reduced nitric oxide synthesis, can promote the onset and progression of atherosclerosis in experimental models. This review discusses the current role of ADMA and DDAH in vascular health and disease, the techniques used to assess DDAH activity and expression, and the results of recent studies on pharmacological and biological agents modulating DDAH activity and expression. Suggestions for future basic and clinical research directions are also discussed.
Original languageEnglish
Pages (from-to)303-319
Number of pages17
JournalExpert Opinion on Drug Metabolism and Toxicology
Issue number3
Publication statusPublished - 1 Mar 2009


  • Amidohydrolases
  • Animals
  • Arginine
  • Cardiovascular Agents
  • Cardiovascular Diseases
  • Disease Progression
  • Drug Delivery Systems
  • Gene Expression Regulation, Enzymologic
  • Humans
  • Nitric Oxide
  • asymmetric dimethylarginine
  • atherosclerosis
  • dimethylarginine dimethylaminohydrolase
  • endothelium
  • nitric oxide


Dive into the research topics of 'Dimethylarginine dimethylaminohydrolase regulation'. Together they form a unique fingerprint.

Cite this